Valuation: AbbVie Inc.

Market Cap 521B 17,563B 465B 427B 388B 728B 49,333B 743B 5,099B 2,055B 26,039B 1,956B 1,914B 82,244B P/E 2026 *
36.7x
P/E 2027 * 28x
Enterprise Value 583B 19,648B 520B 478B 434B 815B 55,189B 831B 5,705B 2,299B 29,129B 2,188B 2,141B 92,006B EV / Sales 2026 *
8.6x
EV / Sales 2027 * 7.8x
Free-Float
95.71%
Yield 2026 *
2.35%
Yield 2027 * 2.46%
1 day-1.98%
1 week+3.12%
Current month-1.98%
1 month+11.86%
3 months+15.12%
6 months+50.00%
Current year+35.62%
1 week 9.55
Extreme 9.55
10.1
1 month 8.7
Extreme 8.7
10.1
Current year 6.25
Extreme 6.25
10.1
1 year 6.25
Extreme 6.25
10.1
3 years 6.25
Extreme 6.25
10.1
5 years 6.25
Extreme 6.25
10.1
10 years 6.25
Extreme 6.25
10.1
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Change 5-day change 1-year change 3-year change Capi.($)
-1.98%+3.12% - - 521B
-0.74%+9.95%+56.87%+142.37% 1,263B
-1.31%+1.13%+44.59%+79.25% 658B
-2.14%+0.30%+35.68%+100.75% 521B
-1.54%+0.18%+53.06%+66.79% 391B
-0.55%+5.82%+80.37%+44.67% 369B
-1.69%+3.17%+32.18%+55.35% 307B
-0.72%+7.83%+12.10%+33.76% 290B
+0.21%+4.92%+57.44%+74.98% 252B
+0.02%+7.32%+39.53%+109.65% 212B
Average -1.08%+5.90%+45.76%+78.62% 473.55B
Weighted average by Cap. -1.17%+6.60%+48.42%+92.88%

Financials

2026 *2027 *
Net sales 67.82B 2,286B 60.55B 55.56B 50.54B 94.76B 6,420B 96.64B 664B 267B 3,389B 255B 249B 10,703B 73.79B 2,487B 65.88B 60.45B 54.99B 103B 6,986B 105B 722B 291B 3,687B 277B 271B 11,646B
Net income 15.98B 539B 14.27B 13.09B 11.91B 22.33B 1,513B 22.77B 156B 63.03B 798B 59.97B 58.69B 2,522B 19.08B 643B 17.03B 15.63B 14.22B 26.65B 1,806B 27.19B 187B 75.25B 953B 71.59B 70.07B 3,011B
Net Debt 61.85B 2,085B 55.22B 50.67B 46.09B 86.42B 5,855B 88.14B 605B 244B 3,091B 232B 227B 9,761B 54.18B 1,826B 48.37B 44.39B 40.38B 75.7B 5,129B 77.21B 530B 214B 2,707B 203B 199B 8,551B
Projected Income Statement - Annual - AbbVie Inc.
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
02/11/26 THB 9.900 -1.98% 18,773
30/10/26 THB 10.10 +3.06% 32,066
29/10/26 THB 9.800 +1.03% 11,185
28/10/26 THB 9.700 +0.52% 982
27/10/26 THB 9.650 -0.52% 638
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AbbVie Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
294.89USD
Average target price
298.50USD
Spread / Average Target
+1.22%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AbbVie Inc.